LSTA Stock Analysis: Buy, Sell, or Hold?
LSTA - Lisata Therapeutics, Inc. Common Stock
$5.02
0.01 (0.20%)
▲
5d:
+0.0%
30d:
+16.47%
90d:
+169.89%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When LSTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LSTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LSTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LSTA is currently trading at $5.02, which is considered slightly high relative to its 30-day fair value range of $4.43 to $5.12.
Technical Outlook: Technically, LSTA is in a strong uptrend. The price is currently testing key support at $5.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+89.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LSTA is in a strong uptrend. The price is currently testing key support at $5.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+89.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$4.43 -
$5.12
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.2% below Wall St target ($9.50)
Fair Price Analysis
30-Day Fair Range
$4.43 -
$5.12
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.00
Resistance Level
$5.04
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.61
Wall Street Target
$9.50
(+89.2%)
Revenue Growth (YoY)
-90.0%
Share & Embed Analysis
Last updated: April 02, 2026 5:25 PM ET
Data refreshes hourly during market hours. Next update: 6:25 PM
Data refreshes hourly during market hours. Next update: 6:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LSTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
